CN109312306A - 产生视网膜组织的方法 - Google Patents
产生视网膜组织的方法 Download PDFInfo
- Publication number
- CN109312306A CN109312306A CN201780036967.7A CN201780036967A CN109312306A CN 109312306 A CN109312306 A CN 109312306A CN 201780036967 A CN201780036967 A CN 201780036967A CN 109312306 A CN109312306 A CN 109312306A
- Authority
- CN
- China
- Prior art keywords
- cell
- transduction pathway
- signal transduction
- culture
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002207 retinal effect Effects 0.000 title claims abstract description 181
- 238000000034 method Methods 0.000 title claims abstract description 114
- 210000004027 cell Anatomy 0.000 claims abstract description 756
- 239000000126 substance Substances 0.000 claims abstract description 674
- 230000019491 signal transduction Effects 0.000 claims abstract description 544
- 239000001963 growth medium Substances 0.000 claims abstract description 384
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 339
- 230000002776 aggregation Effects 0.000 claims abstract description 288
- 238000004220 aggregation Methods 0.000 claims abstract description 288
- 230000003213 activating effect Effects 0.000 claims abstract description 235
- 210000000130 stem cell Anatomy 0.000 claims abstract description 168
- 210000001525 retina Anatomy 0.000 claims abstract description 160
- 102000003693 Hedgehog Proteins Human genes 0.000 claims abstract description 122
- 108090000031 Hedgehog Proteins Proteins 0.000 claims abstract description 122
- 210000001519 tissue Anatomy 0.000 claims description 237
- 102000013814 Wnt Human genes 0.000 claims description 147
- 108050003627 Wnt Proteins 0.000 claims description 147
- 230000037361 pathway Effects 0.000 claims description 121
- 238000004519 manufacturing process Methods 0.000 claims description 114
- 238000010361 transduction Methods 0.000 claims description 111
- 230000026683 transduction Effects 0.000 claims description 111
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 claims description 59
- 210000001164 retinal progenitor cell Anatomy 0.000 claims description 53
- 210000002569 neuron Anatomy 0.000 claims description 52
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 51
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 51
- 238000004114 suspension culture Methods 0.000 claims description 51
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 230000000694 effects Effects 0.000 claims description 37
- 239000006185 dispersion Substances 0.000 claims description 33
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 33
- 238000012360 testing method Methods 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 20
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 230000001886 ciliary effect Effects 0.000 claims description 19
- 210000002469 basement membrane Anatomy 0.000 claims description 18
- 230000006698 induction Effects 0.000 claims description 17
- 239000002243 precursor Substances 0.000 claims description 17
- -1 morphine amine Chemical class 0.000 claims description 15
- 230000001988 toxicity Effects 0.000 claims description 15
- 231100000419 toxicity Toxicity 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 241000289669 Erinaceus europaeus Species 0.000 claims description 12
- 210000000981 epithelium Anatomy 0.000 claims description 12
- 210000002287 horizontal cell Anatomy 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 210000005157 neural retina Anatomy 0.000 claims description 8
- ZGSXEXBYLJIOGF-UHFFFAOYSA-N iwr-1-endo Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)C2C(C=C3)CC3C2C1=O ZGSXEXBYLJIOGF-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 6
- 210000004379 membrane Anatomy 0.000 claims description 6
- 239000000790 retinal pigment Substances 0.000 claims description 6
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 5
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 5
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 claims description 5
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 5
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 5
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 claims description 5
- 210000002592 gangliocyte Anatomy 0.000 claims description 5
- 229960005181 morphine Drugs 0.000 claims description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Natural products O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 210000003569 retinal bipolar cell Anatomy 0.000 claims description 2
- 239000012679 serum free medium Substances 0.000 description 110
- VFSUUTYAEQOIMW-YHBQERECSA-N 3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide Chemical compound C1C[C@@H](NC)CC[C@@H]1N(C(=O)C1=C(C2=CC=CC=C2S1)Cl)CC1=CC=CC(C=2C=CN=CC=2)=C1 VFSUUTYAEQOIMW-YHBQERECSA-N 0.000 description 108
- 210000002966 serum Anatomy 0.000 description 85
- 230000014509 gene expression Effects 0.000 description 65
- ZGSXEXBYLJIOGF-ALFLXDJESA-N IWR-1-endo Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)[C@@H]2[C@H](C=C3)C[C@H]3[C@@H]2C1=O ZGSXEXBYLJIOGF-ALFLXDJESA-N 0.000 description 60
- 238000012545 processing Methods 0.000 description 46
- 238000005516 engineering process Methods 0.000 description 38
- 108010085895 Laminin Proteins 0.000 description 36
- 102000007547 Laminin Human genes 0.000 description 36
- 108091006088 activator proteins Proteins 0.000 description 34
- DPDZHVCKYBCJHW-UHFFFAOYSA-N 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCCOC3=CC=2)=C(C=2N=CC=CC=2)N1 DPDZHVCKYBCJHW-UHFFFAOYSA-N 0.000 description 30
- OGKYMFFYOWUTKV-UHFFFAOYSA-N N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide Chemical compound C1=NC=C2C(S(=O)(=O)NCCN)=CC=C(Cl)C2=C1 OGKYMFFYOWUTKV-UHFFFAOYSA-N 0.000 description 29
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 28
- 239000003112 inhibitor Substances 0.000 description 28
- 210000002894 multi-fate stem cell Anatomy 0.000 description 27
- 239000000306 component Substances 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000012423 maintenance Methods 0.000 description 23
- 108700024442 Nodal Proteins 0.000 description 22
- 239000003550 marker Substances 0.000 description 21
- 241000196324 Embryophyta Species 0.000 description 20
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 20
- 101150021185 FGF gene Proteins 0.000 description 19
- 230000004069 differentiation Effects 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 210000004126 nerve fiber Anatomy 0.000 description 19
- 230000004913 activation Effects 0.000 description 17
- 239000007640 basal medium Substances 0.000 description 17
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 17
- 101150086694 SLC22A3 gene Proteins 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 15
- 238000012549 training Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 101150116978 RPE65 gene Proteins 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 108010038862 laminin 10 Proteins 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 108010047118 Wnt Receptors Proteins 0.000 description 10
- 102000006757 Wnt Receptors Human genes 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 238000012744 immunostaining Methods 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 9
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 208000003098 Ganglion Cysts Diseases 0.000 description 8
- 208000005400 Synovial Cyst Diseases 0.000 description 8
- 102000043168 TGF-beta family Human genes 0.000 description 8
- 108091085018 TGF-beta family Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000001671 embryonic stem cell Anatomy 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 241000288906 Primates Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000010129 solution processing Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 6
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 6
- 108091033409 CRISPR Proteins 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101710173438 Late L2 mu core protein Proteins 0.000 description 6
- 108010088225 Nestin Proteins 0.000 description 6
- 102000008730 Nestin Human genes 0.000 description 6
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 6
- 101710188315 Protein X Proteins 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000005055 nestin Anatomy 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 102000000905 Cadherin Human genes 0.000 description 5
- 108050007957 Cadherin Proteins 0.000 description 5
- 102000003505 Myosin Human genes 0.000 description 5
- 108060008487 Myosin Proteins 0.000 description 5
- 101150101169 Rx gene Proteins 0.000 description 5
- 108010031318 Vitronectin Proteins 0.000 description 5
- 102100035140 Vitronectin Human genes 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 239000002771 cell marker Substances 0.000 description 5
- 238000000280 densification Methods 0.000 description 5
- 238000010130 dispersion processing Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000001766 physiological effect Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 230000008672 reprogramming Effects 0.000 description 5
- 230000008093 supporting effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010052946 Activin Receptors Proteins 0.000 description 4
- 102000018918 Activin Receptors Human genes 0.000 description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 4
- 101150081664 PAX6 gene Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108091005735 TGF-beta receptors Proteins 0.000 description 4
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 4
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 4
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000004956 cell adhesive effect Effects 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 102000006533 chordin Human genes 0.000 description 4
- 108010008846 chordin Proteins 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000010363 gene targeting Methods 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 102000045246 noggin Human genes 0.000 description 4
- 108700007229 noggin Proteins 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 108091016585 CD44 antigen Proteins 0.000 description 3
- 241001466804 Carnivora Species 0.000 description 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 101150035427 RDH10 gene Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108090000054 Syndecan-2 Proteins 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000003981 ectoderm Anatomy 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 108010057670 laminin 1 Proteins 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- JNDVEAXZWJIOKB-JYRVWZFOSA-N 3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone Chemical compound CC1=CNC(\C=C/2C3=CC=CC=C3NC\2=O)=C1CCC(O)=O JNDVEAXZWJIOKB-JYRVWZFOSA-N 0.000 description 2
- 101150111620 AQP1 gene Proteins 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 102000005869 Activating Transcription Factors Human genes 0.000 description 2
- 108010005254 Activating Transcription Factors Proteins 0.000 description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 241000202252 Cerberus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 101100239628 Danio rerio myca gene Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 2
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 2
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 2
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 2
- 101000640882 Homo sapiens Retinoic acid receptor RXR-gamma Proteins 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 101150039798 MYC gene Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101150041192 Otx1 gene Proteins 0.000 description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 102100034262 Retinoic acid receptor RXR-gamma Human genes 0.000 description 2
- 102100040756 Rhodopsin Human genes 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- 241001272562 Simiiformes Species 0.000 description 2
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 102000002070 Transferrins Human genes 0.000 description 2
- 108010015865 Transferrins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 102000014823 calbindin Human genes 0.000 description 2
- 108060001061 calbindin Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000000720 eyelash Anatomy 0.000 description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 2
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 101150087532 mitF gene Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 108010055896 polyornithine Proteins 0.000 description 2
- 229920002714 polyornithine Polymers 0.000 description 2
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000003684 theca cell Anatomy 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000002444 unipotent stem cell Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
- GHKCSRZBNZQHKW-UHFFFAOYSA-N 1-sulfanylethanol Chemical class CC(O)S GHKCSRZBNZQHKW-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101710150423 DNA nickase Proteins 0.000 description 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 1
- 239000012824 ERK inhibitor Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- 241001481816 Eulemur mongoz Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000027355 Ferocactus setispinus Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000288984 Loris tardigradus Species 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 101150009249 MAP2 gene Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150111110 NKX2-1 gene Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000010175 Opsin Human genes 0.000 description 1
- 108050001704 Opsin Proteins 0.000 description 1
- 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
- 101150073614 POU4F2 gene Proteins 0.000 description 1
- 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 1
- 101150008375 Pou4f1 gene Proteins 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 101710098761 Protein alpha-1 Proteins 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000018210 Recoverin Human genes 0.000 description 1
- 108010076570 Recoverin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710106192 Short-wave-sensitive opsin 1 Proteins 0.000 description 1
- 241000168914 Strepsirrhini Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940125920 TGFβR inhibitor Drugs 0.000 description 1
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 108091028113 Trans-activating crRNA Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108700020987 Wnt-1 Proteins 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001368 germline stem cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 108010046591 human laminin-511 Proteins 0.000 description 1
- 102000007573 human laminin-511 Human genes 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003552 inferior colliculi Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- QQUXFYAWXPMDOE-UHFFFAOYSA-N kenpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 101150108076 lin28a gene Proteins 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000010449 nuclear transplantation Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000144985 peep Species 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004310 photopic vision Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
Abstract
Description
Claims (32)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016086602 | 2016-04-22 | ||
JP2016-086602 | 2016-04-22 | ||
PCT/JP2017/016120 WO2017183732A1 (ja) | 2016-04-22 | 2017-04-21 | 網膜組織の製造法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109312306A true CN109312306A (zh) | 2019-02-05 |
CN109312306B CN109312306B (zh) | 2023-05-09 |
Family
ID=60116963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780036967.7A Active CN109312306B (zh) | 2016-04-22 | 2017-04-21 | 产生视网膜组织的方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11371016B2 (zh) |
EP (1) | EP3447129B1 (zh) |
JP (1) | JP6995314B2 (zh) |
KR (1) | KR102388863B1 (zh) |
CN (1) | CN109312306B (zh) |
AU (1) | AU2017254264C1 (zh) |
CA (1) | CA3021828A1 (zh) |
ES (1) | ES2928213T3 (zh) |
IL (1) | IL262440B2 (zh) |
SG (1) | SG11201809201UA (zh) |
WO (1) | WO2017183732A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113557311A (zh) * | 2019-03-13 | 2021-10-26 | 大日本住友制药株式会社 | 移植用神经视网膜的品质评价方法及移植用神经视网膜片 |
CN113817679A (zh) * | 2011-11-25 | 2021-12-21 | 住友化学株式会社 | 制备视网膜组织和视网膜相关细胞的方法 |
CN114451357A (zh) * | 2022-01-20 | 2022-05-10 | 中山大学 | 一种基于心肌视黄醇代谢紊乱的成年小鼠心衰模型的构建方法 |
CN117551612A (zh) * | 2024-01-12 | 2024-02-13 | 苏州艾凯利元生物科技有限公司 | 一种视网膜类器官及其制备方法和应用 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11241460B2 (en) | 2013-03-15 | 2022-02-08 | Astellas Institute For Regenerative Medicine | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells |
CN113564123A (zh) | 2014-10-24 | 2021-10-29 | 大日本住友制药株式会社 | 神经组织的制备方法 |
SG11201809201UA (en) * | 2016-04-22 | 2018-11-29 | Sumitomo Dainippon Pharma Co Ltd | Method for producing retinal tissue |
US20200216796A1 (en) * | 2017-07-20 | 2020-07-09 | Riken | Method for Preserving Neural Tissue |
CN110945119B (zh) * | 2017-07-20 | 2024-04-05 | 国立研究开发法人理化学研究所 | 包含连续上皮的视网膜组织的成熟方法 |
EP3680326A4 (en) | 2017-09-08 | 2021-05-19 | Riken | CELLULAR AGGREGATE INCLUDING RETINAL TISSUE, AND CORRESPONDING METHOD OF PRODUCTION |
JP7360583B2 (ja) | 2017-09-14 | 2023-10-13 | 国立研究開発法人理化学研究所 | 網膜組織の製造方法 |
WO2019054515A1 (ja) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法 |
WO2019078781A1 (en) * | 2017-10-17 | 2019-04-25 | National University Of Singapore | SYSTEMS AND METHODS FOR PRODUCING PHOTORECEPTOR PROGENITORS |
US20210071137A1 (en) * | 2017-11-24 | 2021-03-11 | Sumitomo Chemical Company, Limited | Production method for cell mass including neural cells/tissue and non-neural epithelial tissue, and cell mass from same |
SG11202004829WA (en) * | 2017-11-24 | 2020-06-29 | Sumitomo Chemical Co | Method for producing cell mass including pituitary tissue, and cell mass thereof |
CA3122791A1 (en) | 2018-12-28 | 2020-07-02 | Riken | Therapeutic drug for disease accompanied by disorders in retinal cells or retinal tissue |
JPWO2020218480A1 (zh) | 2019-04-26 | 2020-10-29 | ||
GB2584664B (en) * | 2019-06-10 | 2023-05-24 | Newcells Biotech Ltd | Improved retinal organoids and methods of making the same |
JPWO2022054924A1 (zh) | 2020-09-11 | 2022-03-17 | ||
EP4206321A4 (en) | 2020-09-11 | 2024-05-01 | Riken | COMPLEX CONTAINING CELLULAR AGGREGATES CONTAINING NEURAL RETINA, MATRIX AND METHOD OF MANUFACTURING |
JPWO2023003025A1 (zh) * | 2021-07-21 | 2023-01-26 |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1141058A (zh) * | 1993-11-09 | 1997-01-22 | 纽罗斯菲里斯控股有限公司 | 中枢神经系统干细胞的原位修饰和处理 |
CN1630714A (zh) * | 2001-09-21 | 2005-06-22 | 罗切斯特大学 | 干/祖细胞自我更新和分化和时钟控制基因表达的节律控制 |
CN101330935A (zh) * | 2005-10-21 | 2008-12-24 | 细胞研究私人有限公司 | 自脐带羊膜分离和培养干/祖细胞及其分化的细胞的应用 |
EP2128244A1 (en) * | 2007-01-18 | 2009-12-02 | Riken | Method for induction/differentiation into photoreceptor cell |
EP2302036A2 (en) * | 2005-05-27 | 2011-03-30 | Lifescan, Inc. | Amniotic fluid derived cells |
CN102361970A (zh) * | 2008-11-04 | 2012-02-22 | 韦尔赛特公司 | 干细胞聚集体悬浮组合物及其分化方法 |
CN102712900A (zh) * | 2009-10-06 | 2012-10-03 | 首尔大学校产学协力团 | 干细胞分化成为视网膜细胞的方法 |
CN103998599A (zh) * | 2011-11-25 | 2014-08-20 | 住友化学株式会社 | 制备视网膜组织和视网膜相关细胞的方法 |
WO2014134213A1 (en) * | 2013-02-27 | 2014-09-04 | The Regents Of The University Of California | Generation of thymic epithelial progenitor cells in vitro |
WO2015011031A1 (en) * | 2013-07-23 | 2015-01-29 | F. Hoffmann-La Roche Ag | Small molecule based conversion of somatic cells into neural crest cells |
WO2015053375A1 (ja) * | 2013-10-09 | 2015-04-16 | 株式会社ヘリオス | 網膜色素上皮細胞の製造方法 |
WO2015054526A2 (en) * | 2013-10-09 | 2015-04-16 | The Regents Of The University Of California | Methods of mammalian retinal stem cell production and applications |
CN105358680A (zh) * | 2013-04-03 | 2016-02-24 | 细胞动力学国际有限公司 | 用于悬浮培养内胚层祖细胞的方法和组合物 |
CN107002040A (zh) * | 2014-10-24 | 2017-08-01 | 大日本住友制药株式会社 | 视网膜组织的制备方法 |
CN107109367A (zh) * | 2014-10-24 | 2017-08-29 | 大日本住友制药株式会社 | 神经组织的制备方法 |
CN107326009A (zh) * | 2017-05-02 | 2017-11-07 | 深圳百年干细胞技术研究院有限公司 | 使血液单个核细胞逆向分化产生人血源性自体视网膜干细胞的方法、试剂盒及用途 |
CN108064274A (zh) * | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | 用于培养多能干细胞的培养基 |
CN108291206A (zh) * | 2015-09-08 | 2018-07-17 | 富士胶片细胞动力公司 | 干细胞来源的视网膜色素上皮的基于macs 的纯化 |
CN108350421A (zh) * | 2015-09-08 | 2018-07-31 | 大日本住友制药株式会社 | 用于制备视网膜色素上皮细胞的方法 |
AU2017254264A1 (en) * | 2016-04-22 | 2018-11-22 | Riken | Method for producing retinal tissue |
US20190351103A1 (en) * | 2016-11-25 | 2019-11-21 | Riken | Cell Population for Transplantation and Method for Producing Same |
CN110573610A (zh) * | 2017-03-08 | 2019-12-13 | 大日本住友制药株式会社 | 视网膜色素上皮细胞的制备方法 |
CN110945119A (zh) * | 2017-07-20 | 2020-03-31 | 国立研究开发法人理化学研究所 | 包含连续上皮的视网膜组织的成熟方法 |
CN111094554A (zh) * | 2017-09-14 | 2020-05-01 | 国立研究开发法人理化学研究所 | 视网膜组织的制备方法 |
CN111164205A (zh) * | 2017-09-08 | 2020-05-15 | 国立研究开发法人理化学研究所 | 包含视网膜组织的细胞聚集体及其制造方法 |
CN112601814A (zh) * | 2018-08-24 | 2021-04-02 | 住友化学株式会社 | 包含嗅神经细胞或其前体细胞的细胞团块及其制备方法 |
AU2020374884A1 (en) * | 2019-10-30 | 2022-06-09 | Astellas Institute For Regenerative Medicine | Methods for producing retinal pigment epithelium cells |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6878544B2 (en) | 1996-04-19 | 2005-04-12 | Neurotech Sa | Retinal cell lines with extended life-span and their applications |
US20060003446A1 (en) | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
CA2514971C (en) | 2003-02-03 | 2012-08-14 | Japan Science And Technology Agency | Regeneration and neogenesis of retinal photoreceptor cell using otx2 gene |
EP1783205B1 (en) | 2004-06-18 | 2024-02-21 | Riken | Method of inducing the differentiation of embryonic stem cells into nerve by serum-free suspension culture |
DE102004055615A1 (de) | 2004-11-16 | 2006-05-18 | Universitätsklinikum Hamburg-Eppendorf | In vitro aus Knochenmarkstammzellen differenzierte Retina-spezifische Zellen, ihre Herstellung und Verwendung |
JP2008099662A (ja) | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
EP3640326A1 (en) | 2007-04-18 | 2020-04-22 | Hadasit Medical Research Services & Development Limited | Stem cell-derived retinal pigment epithelial cells |
CA3177952A1 (en) | 2007-10-12 | 2009-04-23 | Astellas Institute For Regenerative Medicine | Improved methods of producing rpe cells and compositions of rpe cells |
EP2314671B1 (en) | 2008-06-06 | 2022-08-03 | Riken | Method for culture of stem cell |
BRPI0921726B8 (pt) | 2008-10-31 | 2021-07-27 | Synthes Gmbh | método para preparar uma composição de implante para promover o crescimento ósseo em um mamífero |
WO2011055855A1 (en) | 2009-11-05 | 2011-05-12 | Riken | A method for differentiation induction in cultured stem cells |
JP5928681B2 (ja) | 2010-08-31 | 2016-06-01 | 国立大学法人 千葉大学 | ヒト多能性幹細胞からの造血幹細胞の効率的な誘導方法 |
US9181529B2 (en) | 2010-10-19 | 2015-11-10 | Cellular Dynamics International, Inc. | Titration of differentiation medium components |
US9487752B2 (en) | 2011-03-30 | 2016-11-08 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
EP2774983B1 (en) | 2011-10-31 | 2019-05-15 | Riken | Method for culturing stem cell |
ES2873097T3 (es) | 2012-06-08 | 2021-11-03 | Sumitomo Chemical Co | Método para producir una estructura de tipo zona marginal ciliar |
AU2014303443B2 (en) | 2013-08-06 | 2020-11-12 | Riken | Method for producing anterior eye segment tissue |
EP3037524B8 (en) | 2013-08-23 | 2020-03-04 | Sumitomo Chemical Company, Limited | Method for producing retinal tissue and retina-related cells |
CA2930092C (en) * | 2013-11-11 | 2024-03-12 | Sumitomo Chemical Company, Limited | Method for producing retinal pigment epithelial cells |
DK3081637T3 (da) | 2013-12-11 | 2019-08-12 | Sumitomo Chemical Co | Fremgangsmåde til fremstilling af en ciliær marginalzonelignende struktur |
CA2937129A1 (en) | 2014-01-17 | 2015-07-23 | Sumitomo Chemical Company, Limited | Method for manufacturing ciliary margin stem cells |
KR101712556B1 (ko) | 2014-08-27 | 2017-03-08 | 서울대학교산학협력단 | 줄기세포를 망막신경절세포로 분화시키는 방법 |
EP3192864A4 (en) | 2014-09-08 | 2018-05-30 | Riken | Method for producing cerebellar progenitor tissue |
CA2998091A1 (en) | 2015-09-08 | 2017-03-16 | Sumitomo Dainippon Pharma Co., Ltd. | Method for producing retinal tissue |
-
2017
- 2017-04-21 SG SG11201809201UA patent/SG11201809201UA/en unknown
- 2017-04-21 AU AU2017254264A patent/AU2017254264C1/en active Active
- 2017-04-21 CN CN201780036967.7A patent/CN109312306B/zh active Active
- 2017-04-21 US US16/095,339 patent/US11371016B2/en active Active
- 2017-04-21 ES ES17786064T patent/ES2928213T3/es active Active
- 2017-04-21 KR KR1020187033745A patent/KR102388863B1/ko active IP Right Grant
- 2017-04-21 CA CA3021828A patent/CA3021828A1/en active Pending
- 2017-04-21 WO PCT/JP2017/016120 patent/WO2017183732A1/ja active Application Filing
- 2017-04-21 EP EP17786064.0A patent/EP3447129B1/en active Active
- 2017-04-21 JP JP2018513236A patent/JP6995314B2/ja active Active
-
2018
- 2018-10-17 IL IL262440A patent/IL262440B2/en unknown
Patent Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1141058A (zh) * | 1993-11-09 | 1997-01-22 | 纽罗斯菲里斯控股有限公司 | 中枢神经系统干细胞的原位修饰和处理 |
CN1630714A (zh) * | 2001-09-21 | 2005-06-22 | 罗切斯特大学 | 干/祖细胞自我更新和分化和时钟控制基因表达的节律控制 |
EP2302036A2 (en) * | 2005-05-27 | 2011-03-30 | Lifescan, Inc. | Amniotic fluid derived cells |
CN101330935A (zh) * | 2005-10-21 | 2008-12-24 | 细胞研究私人有限公司 | 自脐带羊膜分离和培养干/祖细胞及其分化的细胞的应用 |
EP2128244A1 (en) * | 2007-01-18 | 2009-12-02 | Riken | Method for induction/differentiation into photoreceptor cell |
CN102361970A (zh) * | 2008-11-04 | 2012-02-22 | 韦尔赛特公司 | 干细胞聚集体悬浮组合物及其分化方法 |
CN102712900A (zh) * | 2009-10-06 | 2012-10-03 | 首尔大学校产学协力团 | 干细胞分化成为视网膜细胞的方法 |
CN103998599A (zh) * | 2011-11-25 | 2014-08-20 | 住友化学株式会社 | 制备视网膜组织和视网膜相关细胞的方法 |
WO2014134213A1 (en) * | 2013-02-27 | 2014-09-04 | The Regents Of The University Of California | Generation of thymic epithelial progenitor cells in vitro |
CN105358680A (zh) * | 2013-04-03 | 2016-02-24 | 细胞动力学国际有限公司 | 用于悬浮培养内胚层祖细胞的方法和组合物 |
WO2015011031A1 (en) * | 2013-07-23 | 2015-01-29 | F. Hoffmann-La Roche Ag | Small molecule based conversion of somatic cells into neural crest cells |
US10724000B2 (en) * | 2013-07-23 | 2020-07-28 | Hoffmann-La Roche Inc. | Small molecule based conversion of somatic cells into neural crest cells |
WO2015053375A1 (ja) * | 2013-10-09 | 2015-04-16 | 株式会社ヘリオス | 網膜色素上皮細胞の製造方法 |
WO2015054526A2 (en) * | 2013-10-09 | 2015-04-16 | The Regents Of The University Of California | Methods of mammalian retinal stem cell production and applications |
CN105814192A (zh) * | 2013-10-09 | 2016-07-27 | 加利福尼亚大学董事会 | 哺乳动物视网膜干细胞产生方法和应用 |
CN105829526A (zh) * | 2013-10-09 | 2016-08-03 | 希里欧斯株式会社 | 用于纯化视网膜色素上皮细胞的方法 |
CN108064274A (zh) * | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | 用于培养多能干细胞的培养基 |
CN107109367A (zh) * | 2014-10-24 | 2017-08-29 | 大日本住友制药株式会社 | 神经组织的制备方法 |
CN107002040A (zh) * | 2014-10-24 | 2017-08-01 | 大日本住友制药株式会社 | 视网膜组织的制备方法 |
EP3211072A1 (en) * | 2014-10-24 | 2017-08-30 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for nerve tissue |
CN113564123A (zh) * | 2014-10-24 | 2021-10-29 | 大日本住友制药株式会社 | 神经组织的制备方法 |
CN113528443A (zh) * | 2014-10-24 | 2021-10-22 | 大日本住友制药株式会社 | 视网膜组织的制备方法 |
CN108291206A (zh) * | 2015-09-08 | 2018-07-17 | 富士胶片细胞动力公司 | 干细胞来源的视网膜色素上皮的基于macs 的纯化 |
CN108350421A (zh) * | 2015-09-08 | 2018-07-31 | 大日本住友制药株式会社 | 用于制备视网膜色素上皮细胞的方法 |
AU2017254264A1 (en) * | 2016-04-22 | 2018-11-22 | Riken | Method for producing retinal tissue |
US20190351103A1 (en) * | 2016-11-25 | 2019-11-21 | Riken | Cell Population for Transplantation and Method for Producing Same |
CN110573610A (zh) * | 2017-03-08 | 2019-12-13 | 大日本住友制药株式会社 | 视网膜色素上皮细胞的制备方法 |
CN107326009A (zh) * | 2017-05-02 | 2017-11-07 | 深圳百年干细胞技术研究院有限公司 | 使血液单个核细胞逆向分化产生人血源性自体视网膜干细胞的方法、试剂盒及用途 |
CN110945119A (zh) * | 2017-07-20 | 2020-03-31 | 国立研究开发法人理化学研究所 | 包含连续上皮的视网膜组织的成熟方法 |
CN111164205A (zh) * | 2017-09-08 | 2020-05-15 | 国立研究开发法人理化学研究所 | 包含视网膜组织的细胞聚集体及其制造方法 |
CN111094554A (zh) * | 2017-09-14 | 2020-05-01 | 国立研究开发法人理化学研究所 | 视网膜组织的制备方法 |
CN112601814A (zh) * | 2018-08-24 | 2021-04-02 | 住友化学株式会社 | 包含嗅神经细胞或其前体细胞的细胞团块及其制备方法 |
AU2020374884A1 (en) * | 2019-10-30 | 2022-06-09 | Astellas Institute For Regenerative Medicine | Methods for producing retinal pigment epithelium cells |
Non-Patent Citations (4)
Title |
---|
FUMITAKA OSAKADA1等: ""In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction"", 《JOURNAL OF CELL SCIENCE》 * |
YANG DU等: ""Regulation of Retinal Progenitor Cell Differentiation by Bone Morphogenetic Protein 4 Is Mediated by the Smad/Id Cascade"", 《RETINAL CELL BIOLOGY》 * |
吴昊芊;彭广华;阴正勤;: "Mitf和Pax6基因在小鼠胚胎干细胞向视网膜色素上皮细胞分化过程中的表达" * |
高珍;彭广华;: "小分子化合物在干细胞诱导分化为视网膜色素上皮细胞中的应用" * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113817679A (zh) * | 2011-11-25 | 2021-12-21 | 住友化学株式会社 | 制备视网膜组织和视网膜相关细胞的方法 |
CN113557311A (zh) * | 2019-03-13 | 2021-10-26 | 大日本住友制药株式会社 | 移植用神经视网膜的品质评价方法及移植用神经视网膜片 |
CN114451357A (zh) * | 2022-01-20 | 2022-05-10 | 中山大学 | 一种基于心肌视黄醇代谢紊乱的成年小鼠心衰模型的构建方法 |
CN117551612A (zh) * | 2024-01-12 | 2024-02-13 | 苏州艾凯利元生物科技有限公司 | 一种视网膜类器官及其制备方法和应用 |
CN117551612B (zh) * | 2024-01-12 | 2024-03-08 | 苏州艾凯利元生物科技有限公司 | 一种视网膜类器官及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2017254264C1 (en) | 2023-10-05 |
EP3447129A4 (en) | 2019-10-30 |
US11371016B2 (en) | 2022-06-28 |
KR20180135482A (ko) | 2018-12-20 |
US20190127690A1 (en) | 2019-05-02 |
IL262440B2 (en) | 2023-06-01 |
JP6995314B2 (ja) | 2022-02-21 |
ES2928213T3 (es) | 2022-11-16 |
CA3021828A1 (en) | 2017-10-26 |
IL262440A (en) | 2018-12-31 |
AU2017254264A1 (en) | 2018-11-22 |
JPWO2017183732A1 (ja) | 2019-02-28 |
CN109312306B (zh) | 2023-05-09 |
KR102388863B1 (ko) | 2022-04-22 |
EP3447129A1 (en) | 2019-02-27 |
EP3447129B1 (en) | 2022-07-20 |
SG11201809201UA (en) | 2018-11-29 |
AU2017254264B2 (en) | 2023-01-19 |
WO2017183732A1 (ja) | 2017-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109312306A (zh) | 产生视网膜组织的方法 | |
JP7088496B2 (ja) | 網膜組織の製造方法 | |
JP7075556B2 (ja) | 神経組織の製造方法 | |
CN105829527A (zh) | 用于制备视网膜色素上皮细胞的方法 | |
CN105960454B (zh) | 用于制备睫状缘区样结构的方法 | |
KR102297580B1 (ko) | 전안부 조직의 제조 방법 | |
US20150132787A1 (en) | Method for producing ciliary marginal zone-like structure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Japan's Osaka City of Osaka Applicant after: SUMITOMO PHARMACEUTICALS CO.,LTD. Applicant after: RIKEN Applicant after: SUMITOMO CHEMICAL Co.,Ltd. Address before: Japan's Osaka City of Osaka Applicant before: Dainippon Sumitomo Pharma Co.,Ltd. Applicant before: RIKEN Applicant before: SUMITOMO CHEMICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240229 Address after: Osaka Prefecture, Japan Patentee after: SUMITOMO PHARMACEUTICALS CO.,LTD. Country or region after: Japan Patentee after: RIKEN Address before: Japan's Osaka City of Osaka Patentee before: SUMITOMO PHARMACEUTICALS CO.,LTD. Country or region before: Japan Patentee before: RIKEN Patentee before: SUMITOMO CHEMICAL Co.,Ltd. |